

August 31, 2022



# Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- [Atara Biotherapeutics, Inc.](#) (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Citigroup 17<sup>th</sup> Annual Biopharma Conference on Wednesday, September 7, 2022 at 6:40 a.m. PDT / 9:40 a.m. EDT.

A live webcast of the presentation will be available by visiting the [Investor Events and Presentations](#) section of [atarabio.com](#). An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

## About Atara Biotherapeutics, Inc.

[Atara Biotherapeutics, Inc.](#) ([@Atarabio](#)) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel<sup>®</sup> (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco. For additional information about the company, please visit [atarabio.com](#) and follow us on [Twitter](#) and [LinkedIn](#).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20220830005945/en/>

## INVESTORS & MEDIA:

### *Investors*

Eric Hyllengren

805-395-9669

[ehyllengren@atarabio.com](mailto:ehyllengren@atarabio.com)

***Media***

Alex Chapman

805-456-4772

[achapman@atarabio.com](mailto:achapman@atarabio.com)

Source: Atara Biotherapeutics, Inc.